EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Intralesional implant for treatment of primary oral malignant melanoma in dogs


Journal of the American Veterinary Medical Association 204(2): 229-236
Intralesional implant for treatment of primary oral malignant melanoma in dogs
The feasibility, safety, and efficacy of a new method of local, sustained-release chemotherapy by use of intralesional cisplatin implants were evaluated in the treatment of oral malignant melanoma. The implant is an injectable viscous gel composed of a protein carrier matrix, a vasoactive modifier, and a chemotherapeutic drug. Twenty dogs with biopsy-proven melanomas were treated at 1- to 2-week intervals by injection with cisplatin implant. Tumors were treated until they resolved or were judged to be unresponsive. In 3 dogs with tumors unresponsive to cisplatin implants, methotrexate implants were used, and in 2 of these dogs, carmustine implants followed the methotrexate. Tumor responses were evaluated by sequential measurements. Melanomas in 14 (70%) of 20 dogs had a gt 50% decrease in volume, and in 11 (55%) of these dogs, had a complete response. Tumors with complete responses received a mean cisplatin dose of 11.7 +- 1.8 mg, delivered in a mean of 2.6 treatments. Two of the dogs with complete response also were treated with methotrexate and carmustine. Implants were well tolerated. Local necrosis, limited to the treatment site, developed in most tumors (17/20) and was associated with tumor response. Systemic toxicosis was minimal; renal insufficiency after cisplatin implants was not evident. Median survival times of dogs with complete tumor response (51 weeks) was substantially greater than that of dogs without local tumor control (10.5 weeks). Recursive partitioning analysis of variables indicated that mandibular tumors of short duration were associated with a positive outcome. Multivariate linear regression analysis revealed the benefit of a greater number of cisplatin implants in a consistent weekly treatment course. The success of the intralesional chemotherapy indicated that implants are a technically feasible modality for local control of oral melanomas in dogs and provide possible alternative treatment to radiation therapy or surgery.


Accession: 002416158

PMID: 8144382

DOI: 10.1111/j.1748-5827.1995.tb02760.x



Related references

Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer 41(6): 2456-2463, 1978

Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. American Journal of Veterinary Research 72(12): 1631-1638, 2012

Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 224(3): 388-394, 2004

Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Veterinary and Comparative Oncology 12(1): 78-84, 2014

Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer 37(2): 684-692, 1976

Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006-2012). Journal of the American Veterinary Medical Association 247(10): 1146-1153, 2016

Intralesional treatment of advanced malignant melanoma with natural interferon. Blut 51(3): 234, 1985

Primary malignant melanoma of the oral cavity--its histological classification and treatment. British Journal of Oral & Maxillofacial Surgery 32(1): 39-47, 1994

A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma. Human Gene Therapy 12(11): 1459-1480, 2001

Treatment and prognosis of primary malignant melanoma of the oral cavity an analysis of 12 out of 96 reported cases. Journal of Japan Society for Cancer Therapy 25(10): 2499-2510, 1990